GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » EV-to-FCF

Access Bio (XKRX:950130) EV-to-FCF : 0.56 (As of May. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Access Bio's Enterprise Value is ₩-62,400 Mil. Access Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-110,881 Mil. Therefore, Access Bio's EV-to-FCF for today is 0.56.

The historical rank and industry rank for Access Bio's EV-to-FCF or its related term are showing as below:

XKRX:950130' s EV-to-FCF Range Over the Past 10 Years
Min: -316.18   Med: -14.89   Max: 33.47
Current: 0.56

During the past 12 years, the highest EV-to-FCF of Access Bio was 33.47. The lowest was -316.18. And the median was -14.89.

XKRX:950130's EV-to-FCF is ranked better than
92.39% of 92 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.315 vs XKRX:950130: 0.56

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-29), Access Bio's stock price is ₩6940.00. Access Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1243.000. Therefore, Access Bio's PE Ratio for today is At Loss.


Access Bio EV-to-FCF Historical Data

The historical data trend for Access Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio EV-to-FCF Chart

Access Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.04 31.44 3.42 - -0.26

Access Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 1.08 -0.47 -0.26 0.38

Competitive Comparison of Access Bio's EV-to-FCF

For the Diagnostics & Research subindustry, Access Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Access Bio's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Access Bio's EV-to-FCF falls into.



Access Bio EV-to-FCF Calculation

Access Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-62400.025/-110880.786
=0.56

Access Bio's current Enterprise Value is ₩-62,400 Mil.
Access Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-110,881 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Access Bio  (XKRX:950130) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Access Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6940.00/-1243.000
=At Loss

Access Bio's share price for today is ₩6940.00.
Access Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1243.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Access Bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Access Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio (XKRX:950130) Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio (XKRX:950130) Headlines

No Headlines